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There is considerable evidence to suggest that prostaglandins play an important role in the development and growth of cancer. The
enzyme cyclo-oxygenase (COX) catalyses the conversion of arachidonic acid to prostaglandins. In recent years, there has been
interest in a possible role for COX inhibitors in the prevention and treatment of malignancy. Cyclo-oxygenase-2 (COX-2) is
overexpressed in several epithelial tumours, including breast cancer. Preclinical evidence favours an antitumour role for COX
inhibitors in breast cancer. However, the epidemiological evidence for an association is conflicting. Trials are being conducted to study
the use of COX inhibitors alone and in combination with other agents in the chemoprevention of breast cancer, and in the neo-
adjuvant, adjuvant, and metastatic treatment settings. In evaluating the potential use of these agents particularly in cancer
chemoprophylaxis, the safety profile is as important as their efficacy. Concern over the cardiovascular safety of both selective and
nonselective COX-inhibitors has recently been highlighted.
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Breast cancer is the most common malignancy in women in
industrialised nations and the second leading cause of female
cancer-related mortality. Approximately 40000 women develop
breast cancer in the UK each year. The incidence of breast cancer
has increased by two-thirds over the last 15 years. Mortality rates
though have fallen by one-third, and this is likely to be due to
earlier detection of breast cancer because of screening, and the
increased use of adjuvant therapies. In recent times, the prospect
of further improvements in mortality rates has grown with hope
provided by new chemotherapy agents and monoclonal antibody
therapy directed at cell surface molecules. But can we do even
better for women with breast cancer using cheap and simple
treatments that are in current use?
Nonsteroidal anti-inflammatory drugs (NSAIDs) are a group of
widely available, inexpensive medicines. The analgesic, anti-
inflammatory, antipyretic and antithrombotic effects of salicylate
in willow bark and other plant extracts were recognised in ancient
Egypt and Greece. These properties have been extensively
exploited in numerous fields of clinical medicine since the 19th
century, and in cancer patients primarily for analgesia.
Nonsteroidal anti-inflammatory drugs inhibit the enzyme cyclo-
oxygenase (COX), which catalyses the conversion of arachidonic
acid to prostaglandins (PGs). Prostaglandins are important
mediators of signal transduction pathways and are involved in
cellular adhesion, growth and differentiation. In recent years,
interest has been aroused in a possible role for aspirin and other
NSAIDs in the prevention of malignancy. The most persuasive
evidence to date relates to colorectal cancer. Meta-analyses of
observational studies suggest that NSAIDs reduce the risk of
colorectal cancer by around a half (Garcia Rodriguez and Huerta-
Alvarez, 2000). For this reason, the US Food and Drug Adminis-
tration has approved the use of the selective COX-2 inhibitor,
celecoxib, in the prevention of colorectal polyps in patients with
familial adenomatous polyposis.
It has been suggested that there is a possible role for COX
inhibitors in the chemoprevention, and possibly even treatment of
breast cancer. In this article we review the current experimental,
epidemiological and clinical evidence available on the possible
link between COX and breast cancer, coming to a consensus as to
whether COX-inhibition is a worthwhile potential strategy in the
prevention and treatment of breast cancer.
COX AND BREAST CANCER: MOLECULAR
RELATIONSHIP
The biochemistry of COX
NSAIDs inhibit the cyclo-oxygenase enzymes 1 and 2, the rate-
limiting enzymes in the conversion of arachidonic acid to
prostaglandins. The two COX isoforms have distinct tissue
distributions and physiological functions. Cyclo-oxygenase-1 is
constitutively expressed in many tissues and cell types, whereas
the inducible isoenzyme COX-2 is pro-inflammatory in nature and
expressed only in response to certain stimuli such as mitogens,
cytokines, growth factors, or hormones. Specific COX-2 inhibitors
have been developed, and these largely avoid the gastrointestinal
side effects associated with NSAID use, which are thought to be
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mediators of signal transduction pathways and are therefore
involved in cellular adhesion, growth and differentiation.
COX, prostaglandins and breast cancer
There is a clear relationship between tissue prostaglandin levels in
human breast tumours, the development of metastases and
survival (Bennett, 1986). The main product of COX-2, prostaglan-
din E2, is synthesised by several human breast cancer cell lines and
is found at high levels in tumour cells (Screy and Patel, 1995). High
concentrations of prostaglandin E2 have been associated with risk
of metastases and a lack of oestrogen and progesterone receptors
(Fulton and Heppner, 1985).
COX-2 is overexpressed in breast cancer cell lines such as the
highly invasive, metastatic line MDA-MB-231 (Liu and Rose, 1996)
as well as in tumours. In one study, COX-2 expression was detected
by PCR in 13 human breast tumours with no detectable expression
in normal breast tissue (Parrett et al, 1997). A correlation was also
observed between COX-2 expression and increasing tumour cell
density. Contrasting findings come from a series of 44 cases where
COX-2 protein was detected in just two patients (Hwang et al,
1998).
Conclusions become clearer when larger numbers of patients’
tumours are examined. In an immunohistochemical study of 1576
invasive breast carcinomas, there was moderate to strong COX-2
expression in 37% of the samples (Ristimaki et al, 2002). This
observation, which has been replicated in other studies involving
large patient numbers, should be regarded as definitive, and the
evidence from past studies should be disregarded because of the
small sample size.
COX staining is not specific to malignant cells but also
detectable in premalignant breast tissue. A higher frequency of
COX-2 was expressed in ductal carcinoma in situ than invasive
breast cancer, suggesting that COX-2 may have a role in
preinvasive disease. However, all is not as straightforward as it
might first appear. Boland et al (2004) found that there was no
significant difference in COX-2 expression, comparing normal
breast tissue from reduction mammoplasty and normal breast
tissue surrounding ductal carcinoma in situ, and also no difference
in COX-2 expression between ductal carcinoma in situ and
invasive breast cancer.
COX-2 and breast cancer progression
COX-2 expression is correlated with prognostic markers that
reflect a poor chance for survival, which includes tumour size,
axillary node metastases, tumour grade, ductal histology, receptor
negative disease and HER-2 amplification (Ristimaki et al, 2002;
Boland et al, 2004). Moreover, elevated COX-2 expression has
recently been shown to correlate with distant metastases in breast
cancer (Ranger et al, 2004).
COX-2 is related to cancer outlook through direct and indirect
mechanisms. Prostaglandins may directly stimulate mitogenesis
through a direct effect on fibroblasts, osteoblasts, and mammary
cells. Cyclo-oxygenase-2 indirectly affects mutagenesis, angio-
genesis, and increased cell migration and apoptosis (Figure 1).
Celecoxib has been shown to inhibit proliferation of human breast
cancer cell lines (Arun et al, 2001).
The combination of COX-2 inhibitor with standard cancer
chemotherapeutic and/or radiation may provide additional
therapeutic paradigms in the treatment of various human cancers.
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Figure 1 Mechanisms by which COX-2 and PGE2 could modulate mammary tumour development. In epithelial tumours of the mammary gland, COX-2-
derived PGE2 may stimulate proliferation and angiogenesis, enhance invasiveness, protect cells from apoptosis, and modulate immunosuppression. Solid
malignancies are composed of multiple types of cells, which produce signals that work in both a paracrine and autocrine manner as depicted. COX-2,
cyclooxygenase-2; NK, natural killer; EGFR, epidermal growth factor receptor; NSAIDs, nonsteroidal anti-inflammatory drugs; VEGF, vascular endothelial
growth factor; PGE2, prostaglandin E2. Reprinted from Wang D, Raymond ND. Cyclooxygenase-2: a potential target in breast cancer. Semin Oncol 2004; 31
(Suppl 3): 64–73
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AND TREATMENT OF BREAST CANCER
Translational experiments in animal models link COX with breast
cancer. Transgenic mice with the COX-2 gene inserted under the
control of the mouse mammary tumour virus promoter developed
mammary tumours after several cycles of pregnancy and lactation
while virgin animals remain tumour free (Liu et al, 2001). This
provides evidence that overexpression of COX-2 itself is sufficient
to induce tumorigenesis, but of potentially greater clinical
significance is the evidence that if the transgenics were given a
COX-2 inhibitor, mammary tumorigenesis was repressed (Narko
et al, 2005).
In another study using nonselective COX inhibitors, a 35-day
course of ibuprofen administered to rats with carcinogen-induced
mammary tumours, led to a significant reduction in tumour
volume. The tumours showed reduced expression of both COX
isoforms (Robertson et al, 1998).
Specific COX-2 inhibitors can prevent mammary tumours from
developing in experimental animals. Nimesulide reduced the size
and numbers of carcinogen-induced tumours (Nakatsugi et al,
2000) and celecoxib inhibited the development of carcinogen-
induced mammary tumours (Abou-Issa et al, 2001). Celecoxib has
also been showed to significantly delay the onset of HER2/neu-
induced tumours (Howe et al, 2002). HER2/neu-induced mam-
mary tumours and angiogenesis have been shown to be reduced in
COX-2 knockout mice (Howe et al, 2005).
It has been demonstrated that PGE2 stimulates aromatase
transcription leading to increased concentrations of oestrogens
(Harris et al, 1999). Overexpression of COX-2 in breast cancer may
lead to increased PGE2 synthesis and this in turn to progression
of oestrogen-dependent disease. Therefore, inhibition of PGE2
by COX-2 inhibitors may inhibit aromatase activity and when
combined with aromatase inhibitors reduce tumours by inhibiting
a common target. Indeed, there is preclinical data from a rodent
model to suggest that celecoxib when combined with exemestane
significantly inhibits the growth of mammary tumours (Pesenti
et al, 2001).
The antitumorigenic effects of NSAIDs and selective COX-2
inhibitors may involve other mechanisms than COX-2 inhibition:
for example, high concentrations of NSAIDs or selective inhibitors
of COX-2 suppress the growth of cells in culture that do not
express COX-2 (Hwang et al, 2002). Moreover, a recent clinical
trial found that low-dose aspirin, which has virtually no COX-2
inhibitory effects, had a chemoprotective effect in individuals at
increased risk of developing colorectal cancer (Huls et al, 2003).
EPIDEMIOLOGY OF COX INHIBITOR USE AND
BREAST CANCER INCIDENCE
So, the balance of evidence from cell lines and animal models
support the notion that COX-2 may be involved in breast
carcinogenesis, and that COX-2 inhibition could play a preventa-
tive or even a therapeutic role. But what is fact in cell line and
animal models of cancer may be fiction in tumours. What is the
epidemiological evidence for a possible link between COX-2
inhibition and breast cancer?
A recent meta-analysis (Gonzalez-Perez et al, 2003) of nine
case–control studies and seven cohort studies showed a slight but
significant reduction of breast cancer incidence among users of
aspirin and other non-aspirin NSAIDs. There was significant
heterogeneity of results, which is largely explained by the
differences in study designs, exposure assessment, and to a lesser
degree, the inclusion of lag time analysis.
A meta-analysis (Khuder and Mutgi, 2001) of eight case–control
and six cohort studies examined the effect of dose and frequency of
NSAID use on risk reduction. Only two studies provided evidence
of significant trend of risk reduction with increasing exposure to
NSAIDs (Coogan et al, 1999; Sharpe et al, 2000), but there were
insufficient data to estimate the overall combined dose–response
effect for either duration or frequency of use in the meta-analysis.
A recent large prospective cohort analysis attempts to answer
the question of whether increasing frequency and duration of use
of NSAIDs is associated with a reduced risk of breast cancer
(Harris et al, 2003). The US Women’s Health Initiative Observa-
tional Study of 80741 postmenopausal women between the ages of
50 and 79 years, who were followed-up for an average of 43 months
after baseline interview included an assessment of breast cancer
risk factors and NSAID use. There were 1392 confirmed cases of
breast cancer. Regular NSAID usage of two or more tablets a
week for 5–9 years produced a 21% reduction in breast cancer
incidence; NSAID usage for over 10 years produced a 28%
reduction and there was statistically significant inverse linear trend
of breast cancer incidence with the duration of NSAID use. The
estimated risk reduction was greater with ibuprofen than with
aspirin. Subgroup analysis of breast cancer risk factors did not
result in effect modification. Regular use of low-dose aspirin and
acetaminophen was unrelated to the risk of breast cancer.
This result is at odds with the findings of another large study
involving 734 899 women in a nested case–control design. This
study, using the General Practice Research Database, found a
protective role for aspirin and paracetamol if taken for one year or
longer, with daily doses of aspirin and paracetamol showing
greatest risk reduction. There was no risk reduction for use of non-
aspirin NSAIDs (Garcia Rodriguez and Gonzalez-Perez, 2004).
The dose–response relationship shown by the US Women’s
Health Initiative Observational Study was also illustrated in a
population-based case–control study involving 1442 cases and
1420 controls, comparing aspirin, ibuprofen and acetaminophen.
Here there was a statistically significant inverse association for any
NSAID use, and frequent use. For aspirin use, the effects for
frequency of use were stronger than duration of use. This differs
with ibuprofen use where frequency and duration of use was not
associated with decreasing risk. Acetaminophen was unrelated
to the incidence of breast cancer (Terry et al, 2004). The authors
examined the relationship between the observed risk reduction of
breast cancer in patients taking NSAIDs and hormone receptor
status. They concluded that there was a reduction in risk and this
was mainly of hormone receptor-positive tumours. This result
leads credibility to the theory that the COX-2 inhibitors’ action is
through aromatase inhibition. However, this is the only epide-
miological study so far to show that the mechanism of NSAID
activity is through hormone receptor, and needs to be replicated
before the findings can be accepted as conclusive.
CLINICAL TRIALS INVOLVING COX-2 INHIBITORS
AND BREAST CANCER
Trials are being conducted to study the use of celecoxib alone and
in combination with other agents in chemoprevention, and in the
neo-adjuvant, adjuvant, and metastatic treatment settings. These
are mostly small efficacy safety studies and have so far only
reported on safety profile (Banu and Goss, 2004). For example, a
prospective pilot study recruited 32 patients to study the use of
FEC (5FU 500mgm
2, Epirubicin 75mgm
2, cyclophosphamide
500mgm
2) and celecoxib (400mgbd) as a neo-adjuvant treat-
ment for locally advanced cancer. A total of 16 patients each
were recruited to two arms (FEC alone and FEC together with
celecoxib). The stated end points were clinical, pathologic
responses and tolerability. The clinical and pathological responses
for the combined treatment arms were 81.3 and 87.5, respectively,
vs 62.5 and 62.5% in the single treatment arm. The regimens were
well tolerated with no significant clinical cardiac toxicity.
A phase II randomised trial of trastuzumab, with or without
celecoxib, in a series of 12 patients with metastatic breast cancer
COX inhibitors and breast cancer
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ments, found that there was no treatment effect, although the
drug combination was well tolerated (Dang et al, 2004). This
study consisted only of patients who had been pretreated with
trastuzumab. The effect on treatment-naive patients is still
unknown and being investigated in an ongoing trial. Results of a
randomised phase II study in 111 postmenopausal women with
advanced breast cancer treated with exemestane and celecoxib
indicated a longer time to progression with no additional side
effects from the use of the combination (Dirix et al, 2003).
The high expression of COX-2 in ductal carcinoma in situ
(DCIS) has led to interest in the use of COX-2 inhibitors in this
clinical setting. Studies are now looking at the effect of celecoxib
on both oestrogen (ER) negative and positive DCIS. In addition,
trials have been proposed using adjuvant celecoxib in ER-negative
DCIS to determine whether it prevents recurrence after wide local
excision.
LONG-TERM SAFETY OF COX INHIBITION
Even antiplatelet doses of aspirin cause increase in gastrointestinal
and intracerebral bleeding, especially with prolonged treatment
of large numbers of healthy people. Evidence is now emerging
about the safety of specific COX-2 inhibitors. Earlier studies seem
to confirm improved gastrointestinal tolerance compared with
conventional NSAIDs (Bombardier et al, 2000; Silverstein et al,
2000). However, there were worries about a possible prothrombo-
tic effect of COX-2 inhibitors (Bombardier et al, 2000) and the
recent withdrawal of rofecoxib due to increased cardiovascular
thrombotic risk in the Adenomatous Polyp Prevention on Vioxx
(APPROVe) trial has highlighted new safety concerns about this
class of drugs. The safety of celecoxib is currently being examined
following results from the Adenoma Prevention with Celecoxib
(APC) trial, which found patients taking 400 to 800mgday
1 of
celecoxib had a 2.5- to 3.4-fold increased risk of major fatal or
non-fatal cardiovascular events vs placebo. The use of celecoxib in
this trial has now been suspended. The cardiovascular safety of
conventional NSAIDs has also been recently questioned (Hippisley-
Cox and Coupland, 2005).
A joint meeting of the American Arthritis Advisory Committee
and the Drug Safety and Risk Management Advisory Committee
was convened in early 2005 to review the safety of COX-2
inhibitors. The committee voted unanimously that all of the COX-2
inhibitors currently (or previously) available in the United States
(celecoxib, valdecoxib, rofecoxib) significantly increase the risk of
cardiovascular events in users of these drugs. Considering
potential benefits as well as risks and their magnitude, the
committee voted unanimously in favour of keeping celecoxib on
the market for its current indicated uses. Most panelists favoured
restrictions on direct-to-consumer advertising of COX-2 inhibi-
tors. All voted in favour of requiring future agents in this class
(both COX-2 and nonselective NSAIDs) to perform cardiovascular
safety studies prior to market introduction.
CONCLUSION
So where does this leave us in assessing the role of COX-2 inhibition
for the prevention and treatment of breast cancer in the clinical
setting? Certainly, there is little evidence at present that these drugs
are effective treatments for established breast cancer. Work is
currently in progress to investigate the possible role of COX
inhibitors in limiting the development of invasive breast cancer from
ductal carcinoma-in situ. Also, clinical trials are being conducted to
study the use of specific COX-2 inhibitors both alone and in
combination with other agents in early and advanced breast cancer.
There seems to be a small but potentially significant protective
role of NSAIDs on breast cancer risk. It is not clear if aspirin use is
associated with a different risk reduction compared with other
NSAIDs and, indeed, selective COX-2 inhibitors and questions
remain over drug dosage and patient selection. Table 1 sum-
marises the available data for an association between COX and
breast cancer.
While several mechanisms have been suggested for the anticancer
action of COX inhibitors, it remains unclear which is the most
important and, indeed, whether inhibition of COX-2 is the sole
reason for the effects observed in this context. Also, if there is a
protective role to be played by COX inhibitors in breast cancer,
there are questions of how much drug should be taken and for how
long. Concern over the long-term safety of conventional NSAIDs
and selective COX-2 inhibitors has recently been highlighted. In
evaluating the potential use of NSAIDS in cancer chemoprophylaxis,
the safety profile of these drugs is as important as their efficacy.
On the face of it, at the end of this review, the reader has
probably been left with more questions than there are answers.
However, if the use of aspirin and other NSAIDs is associated with
reduced incidence of breast cancer, this could have a major public
health impact. Work is in progress to detail the possible link of
COX-2 inhibition and breast cancer, and also to assess the long-
term safety and hence viability of this potentially valuable and
viable chemopreventative approach.
Table 1 Overview of studies exploring the association of COX and breast cancer
Author(s) Type of study Finding
Screy and Patel (1995) In vitro PGE2 is synthesised by breast cancer cell lines
Liu and Rose (1996) In vitro COX-2 is overexpressed in MDA-MB-231 breast cancer cells
Ristimaki et al (2002) In vitro COX-2 expression is found in 37% of invasive breast cancers
Arun et al (2001) In vitro Celecoxib inhibits growth of human breast cancer cell lines
Liu et al (2001) Preclinical/in vivo COX-2 overexpression induces mammary tumorigenesis in transgenic mice
Narko et al (2005) Preclinical/in vivo COX-2 inhibitors reduce mammary tumorigenesis in COX-2 transgenic mice
Abou-Issa et al (2001) Preclinical/in vivo Celecoxib inhibits development of carcinogen-induced mammary tumours
Howe et al (2005) Preclinical/in vivo HER-2/neu-induced mammary tumours and angiogenesis are reduced in COX-2
knockout mice
Gonzalez-Perez et al (2003) Epidemiological/meta-analysis of nine
case–control and seven cohort studies
Aspirin and NSAIDs significantly reduce breast cancer risk
Khuder and Mutgi (2001) Epidemiological/meta-analysis of eight
case–control and six cohort studies
Increasing exposure to NSAIDs does not significantly reduce breast cancer risk
Harris et al (2003) Epidemiological (cohort) Regular NSAID use reduces breast cancer incidence; there is an inverse linear trend of
breast cancer incidence with NSAID use duration
Garcia Rodriguez and
Gonzalez-Perez (2004)
Epidemiological (nested case–control) Aspirin use for a year or longer protects against breast cancer development; no risk
reduction seen with other NSAIDs
Terry et al (2004) Epidemiological (case–control) NSAID use (as well as frequency of use) is inversely related to risk of breast cancer
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